Abstract
Background Currently, only dexamethasone, tocilizumab and sarilumab have conclusively been shown to reduce mortality of COVID-19. No drug for prevention or treatment in earlier stages of COVID-19 are yet found; although several new candidates including molnupiravir, ivermectin, baricitinib, budesonide and fluvoxamine are being studied with some early promising results. Safe and effective treatments will need to be both affordable and widely available globally to be used alongside vaccination programmes. This analysis will estimate and compare potential generic production costs of a selection of COVID-19 drug candidates with available international list prices.
Methods Costs of production for new and potential COVID-19 drugs (dexamethasone, ivermectin, fluvoxamine, budesonide, baricitinib, tocilizumab, sarilumab and molnupiravir) were estimated using active pharmaceutical ingredients (API) data extracted from global shipping records. This was compared with national pricing data from a range of low, medium, and high-income countries. Annual API export volumes from India were used to estimate the current availability of each drug.
Results Repurposed therapies can be generically manufactured at very low per-course costs, ranging from $4.16 for fluvoxamine and $2.58 for IV dexamethasone (or $0.19 orally) to $0.55 for ivermectin. No export price data was available for baricitinib, tocilizumab or sarilumab. When compared against international list prices, we found wide variations between countries.
Conclusions Successful management of COVID-19 will require equitable access to treatment for all populations, not just those able to pay high prices. Analysed drugs are widely available and affordable, whilst IV treatment courses are more expensive.
Key Points
Re-purposed drugs under evaluation for COVID-19 must be affordable worldwide to compliment vaccine programmes.
Estimated costs/course were: ivermectin ($0.55), budesonide ($4.34), baricitnib ($6.67), molnupiravir ($255.57), dexamethasone ($0.22), tocilizumab ($410.59), sarilumab (875.70) and fluvoxamine ($4.16).
High drug prices may limit access.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the International Treatment Preparedness Coalition, Make Medicines Affordable Campaign.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No ethical approval was required for this analysis.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Methodology: clarified strategy and rationale for drug selection. Results: revised estimates for ivermectin, removed colchicine and dutasteride, added fluvoxamine, molnupiravir, inhaled budesonide. Discussion: updated.
Data Availability
Data used for this study is available upon request to the authors.
